Shanghai Junshi announces results from JUPITER-02, JUPITER-06 at ESMO

Shanghai Junshi (SHJBF) Biosciences announced new and promising long-term survival results from JUPITER-02 and JUPITER-06 at the European Society for Medical Oncology, ESMO, ASIA Congress 2025. JUPITER-02 and JUPITER-06 evaluated toripalimab, an anti-PD-1 antibody developed by Junshi Biosciences, in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, NPC, in JUPITER-02 and advanced or metastatic esophageal squamous cell carcinoma, ESCC, in JUPITER-06. Key highlights: Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC. The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%.